Entrada Therapeutics (NASDAQ:TRDA) Given “Buy” Rating at HC Wainwright

Entrada Therapeutics (NASDAQ:TRDA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 149.69% from the stock’s current price.

Entrada Therapeutics Stock Performance

TRDA opened at $8.01 on Tuesday. The company has a fifty day moving average price of $8.87 and a two-hundred day moving average price of $13.33. The firm has a market capitalization of $304.00 million, a PE ratio of 5.04 and a beta of 0.04. Entrada Therapeutics has a 52 week low of $7.10 and a 52 week high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The business had revenue of $8.75 million during the quarter, compared to analysts’ expectations of $10.98 million. Equities analysts forecast that Entrada Therapeutics will post 1.12 EPS for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC increased its position in shares of Entrada Therapeutics by 44.0% in the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock valued at $243,000 after buying an additional 4,291 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Entrada Therapeutics in the fourth quarter valued at about $137,000. Charles Schwab Investment Management Inc. grew its stake in Entrada Therapeutics by 6.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company’s stock valued at $3,408,000 after acquiring an additional 11,143 shares during the period. AlphaQuest LLC bought a new stake in shares of Entrada Therapeutics in the fourth quarter worth about $70,000. Finally, American Century Companies Inc. raised its position in shares of Entrada Therapeutics by 17.7% during the fourth quarter. American Century Companies Inc. now owns 59,710 shares of the company’s stock worth $1,032,000 after purchasing an additional 8,985 shares during the period. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.